Patents by Inventor Saumya Roy

Saumya Roy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted bicyclic compounds useful as T cell activators
    Patent number: 11964973
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR6 or N; Y is CR3 or N; R1, R2, R3, R4, R5, R6, R7, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: April 23, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert G. Gentles, Upender Velaparthi, Min Ding, Richard E. Olson, Scott W. Martin, Saumya Roy, Prasada Rao Jalagam, Jayakumar Sankara Warrier, Louis S. Chupak, Denise Christine Grunenfelder
  • COMBINATION OF A T CELL THERAPY AND A DGK INHIBITOR
    Publication number: 20240108654
    Abstract: Provided herein are methods, compositions and uses involving T cell therapies, such as adoptive T cell therapy, and an inhibitor of a Diacylglycerol kinase (DGK). The provided methods, compositions and uses include those involving the administration or use of one or more DGK inhibitors (DGKi) in a combination therapy with a T cell therapy, such as a genetically engineered T cell therapy involving cells engineered with a recombinant receptor, such as chimeric antigen receptor (CAR) or T cell receptor (TCR).
    Type: Application
    Filed: March 2, 2022
    Publication date: April 4, 2024
    Applicant: Juno Therapeutics, Inc.
    Inventors: David G. KUGLER, Jim QIN, Alison MAIER, Richard OLSON, Michael WICHROSKI, Upender VELAPARTHI, Chetan Padmakar DARNE, Bireshwar DASGUPTA, Denise Christine GRUNENFELDER, Jayakumar Sankara WARRIER, Hasibur RAHAMAN, Prasada Rao JALAGAM, Saumya ROY, Pallavur SIVAKUMAR
  • Substituted naphthyridinone compounds useful as T cell activators
    Patent number: 11713316
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R3, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: August 1, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Upender Velaparthi, Louis S. Chupak, Chetan Padmakar Darne, Min Ding, Robert G. Gentles, Yazhong Huang, Manjunatha Narayana Rao Kamble, Scott W. Martin, Raju Mannoori, Ivar M. McDonald, Richard E. Olson, Hasibur Rahaman, Prasada Rao Jalagam, Saumya Roy, Gopikishan Tonukunuru, Sivasudar Velaiah, Jayakumar Sankara Warrier, Xiaofan Zheng, John S. Tokarski, Bireshwar Dasgupta, Kotha Rathnakar Reddy, Thiruvenkadam Raja
  • SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS
    Publication number: 20230151007
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Application
    Filed: November 8, 2022
    Publication date: May 18, 2023
    Inventors: Upender Velaparthi, Richard E. Olson, Chetan Padmakar Darne, Bireshwar Dasgupta, Jayakumar Sankara Warrier, Hasibur Rahaman, Prasada Rao Jalagam, Saumya Roy, Denise Christine Grunenfelder
  • COMBINATIONS OF DGK INHIBITORS AND CHECKPOINT ANTAGONISTS
    Publication number: 20230089255
    Abstract: Provided are inhibitors of diacylglycerol kinases (DGK) and methods for treating diseases that would benefit from the stimulation of the immune system, such as cancer and infections diseases, comprising administering a DGK inhibitor in combination with an antagonist of the PD 1/PD-L 1 axis and/or an antagonist of CTLA4.
    Type: Application
    Filed: December 18, 2020
    Publication date: March 23, 2023
    Inventors: Susan WEE, Joseph L. BENC, Xinyu WANG, Upender VELAPARTHI, Louis S. CHUPAK, Chatan P. DARNE, Min DING, Robert G. GENTLES, Yazhong HUANG, Scott W. MARTIN, Ivar M. MCDONALD, Richard E. OLSON, Xiaofan ZHENG, John S. TOKARSKI, Bireshwar DASGUPTA, Manjunatha Narayana Rao KAMBLE, Raju MANNOORI, Haslbur RAHAMAN, Prasada Rao JALAGAM, Saumya ROY, Gopikishan TONUKUNURU, Sivasudar VELAIAH, Jayakumar Sankara WARRIER, Kotha Rathnakar REDDY, Thiruvenkadam RAJA, Denise GRUNENFELDER, Michael WICHROSKI
  • Substituted pyridopyrimidinonyl compounds useful as T cell activators
    Patent number: 11584747
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: February 21, 2023
    Inventors: Upender Velaparthi, Richard E. Olson, Chetan Padmakar Darne, Bireshwar Dasgupta, Jayakumar Sankara Warrier, Hasibur Rahaman, Prasada Rao Jalagam, Saumya Roy, Denise Christine Grunenfelder
  • SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS
    Publication number: 20220324859
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R3, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Application
    Filed: February 1, 2021
    Publication date: October 13, 2022
    Inventors: Upender Velaparthi, Louis S. Chupak, Chetan Padmakar Darne, Min Ding, Robert G. Gentles, Yazhong Huang, Manjunatha Narayana Rao Kamble, Scott W. Martin, Raju Mannoori, Ivar M. McDonald, Richard E. Olson, Hasibur Rahaman, Prasada Rao Jalagam, Saumya Roy, Gopikishan Tonukunuru, Sivasudar Velaiah, Jayakumar Sankara Warrier, Xiaofan Zheng, John S. Tokarski, Bireshwar Dasgupta, Kotha Rathnakar Reddy, Thiruvenkadam Raja
  • Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
    Patent number: 11253525
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the disclosure.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: February 22, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: James Aaron Balog, Steven P. Seitz, Susheel Jethanand Nara, Saumya Roy, Srinivasan Thangathirupathy, Soodamani Thangavel, Srinivas Cheruku
  • INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE
    Publication number: 20210355113
    Abstract: The present invention provides compounds of formula (I) wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases.
    Type: Application
    Filed: July 20, 2019
    Publication date: November 18, 2021
    Inventors: James Aaron BALOG, Steven P. SEITZ, Jay A. MARKWALDER, David K. WILLIAMS, Weifang SHAN, Susheel Jethanand NARA, Saumya ROY, Srinivas CHERUKU, Nagalakshmi PULICHARLA
  • INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE
    Publication number: 20210299126
    Abstract: The present invention provides compounds of formula (I): wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases.
    Type: Application
    Filed: July 22, 2019
    Publication date: September 30, 2021
    Inventors: James Aaron BALOG, Jay A. MARKWALDER, Weifang SHAN, David K. WILLIAMS, Susheel Jethanand NARA, Saumya ROY, Soodamani THANGAVEL, Srinivas CHERUKU, Ramesh Kumar SISTLA
  • SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS
    Publication number: 20210188845
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR6 or N; Y is CR3 or N; R1, R2, R3, R4, R5, R6, R7, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Application
    Filed: December 22, 2020
    Publication date: June 24, 2021
    Inventors: Robert G. Gentles, Upender Velaparthi, Min Ding, Richard E. Olson, Scott W. Martin, Saumya Roy, Prasada Rao Jalagam, Jayakumar Sankara Warrier, Louis S. Chupak, Denise Christine Grunenfelder
  • Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
    Patent number: 10959986
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the disclosure.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: March 30, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: James Aaron Balog, Steven P. Seitz, Susheel Jethanand Nara, Saumya Roy, Srinivasan Thangathirupathy, Soodamani Thangavel, Ramesh Kumar Sistla
  • Substituted naphthyridinone compounds useful as T cell activators
    Patent number: 10954238
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R3, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: March 23, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Upender Velaparthi, Louis S. Chupak, Chetan Padmakar Darne, Min Ding, Robert G. Gentles, Yazhong Huang, Manjunatha Narayana Rao Kamble, Scott W. Martin, Raju Mannoori, Ivar M. McDonald, Richard E. Olson, Hasibur Rahaman, Prasada Rao Jalagam, Saumya Roy, Gopikishan Tonukunuru, Sivasudar Velaiah, Jayakumar Sankara Warrier, Xiaofan Zheng, John S. Tokarski, Bireshwar Dasgupta, Kotha Rathnakar Reddy, Thiruvenkadam Raja
  • SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS
    Publication number: 20210061802
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Application
    Filed: August 27, 2020
    Publication date: March 4, 2021
    Inventors: Upender Velaparthi, Richard E. Olson, Chetan Padmakar Darne, Bireshwar Dasgupta, Jayakumar Sankara Warrier, Hasibur Rahaman, Prasada Rao Jalagam, Saumya Roy, Denise Christine Grunenfelder
  • Substituted naphthyridinone compounds useful as T cell activators
    Patent number: 10669272
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R3, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: June 2, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Upender Velaparthi, Louis S. Chupak, Chetan Padmakar Darne, Min Ding, Robert G. Gentles, Yazhong Huang, Manjunatha Narayana Rao Kamble, Scott W. Martin, Raju Mannoori, Ivar M. McDonald, Richard E. Olson, Hasibur Rahaman, Prasada Rao Jalagam, Saumya Roy, Gopikishan Tonukunuru, Sivasudar Velaiah, Jayakumar Sankara Warrier, Xiaofan Zheng, John S. Tokarski, Bireshwar Dasgupta, Kotha Rathnakar Reddy, Thiruvenkadam Raja
  • SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS
    Publication number: 20200109140
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R3, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Application
    Filed: June 26, 2019
    Publication date: April 9, 2020
    Inventors: Upender VELAPARTHI, Louis S. Chupak, Chetan Padmakar Darne, Min Ding, Robert G. Gentles, Yazhong Huang, Manjunatha Narayana Rao Kamble, Scott W. Martin, Raju Mannoori, Ivar M. McDonald, Richard E. Olson, Hasibur Rahaman, Prasada Rao Jalagam, Saumya Roy, Gopikishan Tonukunuru, Sivasudar Velaiah, Jayakumar Sankara Warrier, Xiaofan Zheng, John S. Tokarski, Bireshwar Dasgupta, Kotha Rathnakar Reddy, Thiruvenkadam Raja
  • INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE
    Publication number: 20200069646
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the disclosure.
    Type: Application
    Filed: August 29, 2019
    Publication date: March 5, 2020
    Inventors: James Aaron Balog, Steven P. Seitz, Susheel Jethanand Nara, Saumya Roy, Srinivasan Thangathirupathy, Soodamani Thangavel, Ramesh Kumar Sistla
  • INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE
    Publication number: 20200069695
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the disclosure.
    Type: Application
    Filed: August 29, 2019
    Publication date: March 5, 2020
    Inventors: James Aaron Balog, Steven P. Seitz, Susheel Jethanand Nara, Saumya Roy, Srinivasan Thangathirupathy, Soodamani Thangavel, Srinivas Cheruku
  • Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer
    Patent number: 10399933
    Abstract: There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: September 3, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: James Aaron Balog, Weiwei Guo, Audris Huang, Jay A. Markwalder, Weifang Shan, David K. Williams, Susheel Jethanand Nara, Saumya Roy
  • Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer
    Patent number: 10399932
    Abstract: There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: September 3, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: James Aaron Balog, Emily Charlotte Cherney, Jay A. Markwalder, Steven P. Seitz, Weifang Shan, David K. Williams, Audris Huang, Susheel Jethanand Nara, Saumya Roy, Soodamani Thangavel, Ramesh Kumar Sistla, Srinivas Cheruku, Srinivasan Thangathirupathy, Yadagiri Kanyaboina, Nagalakshmi Pulicharla